Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hypertrophic cardiomyopathy (HCM) has been informative as a genetic model of cardiac hypertrophy. Unexpectedly, analysis of the diverse sarcomeric mutations that typically cause HCM has implicated energetic compromise in pathogenesis. Mutations in a regulatory subunit of AMP-activated protein kinase (AMPK) also cause HCM, an effect mediated by glycogen accumulation leading to suppression of total AMPK activity and thus increased protein synthesis. These observations demonstrate the central role of energy homeostasis in cardiac growth and suggest important new treatment strategies. © 2005 Elsevier Ltd. All rights reserved.

Original publication




Journal article


Drug Discovery Today: Disease Mechanisms

Publication Date





129 - 134